Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity

We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule. We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of clinical pathology 2014-06, Vol.141 (6), p.850-855
Hauptverfasser: Albores-Saavedra, Jorge, Dorantes-Heredia, Rita, Chablé-Montero, Fredy, Chanona-Vilchis, José, Pérez-Montiel, Delia, Lino-Silva, Leonardo Saúl, González-Romo, Marco Aurelio, Ramírez-Jaramillo, José Manuel, Henson, Donald E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 855
container_issue 6
container_start_page 850
container_title American journal of clinical pathology
container_volume 141
creator Albores-Saavedra, Jorge
Dorantes-Heredia, Rita
Chablé-Montero, Fredy
Chanona-Vilchis, José
Pérez-Montiel, Delia
Lino-Silva, Leonardo Saúl
González-Romo, Marco Aurelio
Ramírez-Jaramillo, José Manuel
Henson, Donald E
description We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule. We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and leiomyosarcoma were excluded from the study. Data from the Surveillance Epidemiology and End Results program on low- and high-grade ESS for 1973 through 2003 were obtained. One uterine primary ESS had collections of clear cells (20%), while a metastatic ESS contained predominantly clear cells (90%). CD10 (88.2%) and smooth muscle actin (70.5%) were the most common positive immunohistochemical markers. The latter marker was located in the cytoplasm in 47% of the ESS and in the nucleus in 23.5%, a previously unreported feature. HMB45 was detected in 23.5% of the ESS, which contrasts with the 2% reported by other authors. The presence of clear cells and HMB45 reactivity does not justify the term perivascular epithelioid cell tumors for these neoplasms. Two of 17 patients with ESS died of metastatic disease. However, among 274 cases of ESS (all stages included) collected by the Surveillance Epidemiology and End Results Program of the National Cancer Institute during a 30-year period, the 10-year survival rate was 94%.
doi_str_mv 10.1309/AJCPS88CMJRXZBWA
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1526127141</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1526127141</sourcerecordid><originalsourceid>FETCH-LOGICAL-p239t-9d08c4f04885aa59ae6240c74b9cbf718147bc538e59a50107eeea418481e20d3</originalsourceid><addsrcrecordid>eNpd0E1Lw0AQBuBFFFurd08S8OIlOvuR7q63NlRraVH8QPESNsmGrmSTuJso_femWC-e3oF5GF4GoVMMl5iCvJos4ocnIeLV4vHtffo62UNDLBkNOSdkHw0BgIQSczpAR95_AGAigB2iAWGCCkphiFazKq-tbp1RZeBbV9ttKpf1g78OjLVdVTeuLkypg2_TrgNtm7Xyxgd1FcxXUxYFTqusNV-m3Ryjg0KVXp_scoRebmbP8Txc3t_exZNl2BAq21DmIDJWABMiUiqSSo8Jg4yzVGZpwbHAjKdZRIXudxFg4FprxbBgAmsCOR2hi9-7fbPPTvs2scZnuixVpevOJzgiY0w4Zrin5__oR925qm_XK8aYkBi26mynutTqPGmcscptkr9H0R9GWWpC</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1544489101</pqid></control><display><type>article</type><title>Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Albores-Saavedra, Jorge ; Dorantes-Heredia, Rita ; Chablé-Montero, Fredy ; Chanona-Vilchis, José ; Pérez-Montiel, Delia ; Lino-Silva, Leonardo Saúl ; González-Romo, Marco Aurelio ; Ramírez-Jaramillo, José Manuel ; Henson, Donald E</creator><creatorcontrib>Albores-Saavedra, Jorge ; Dorantes-Heredia, Rita ; Chablé-Montero, Fredy ; Chanona-Vilchis, José ; Pérez-Montiel, Delia ; Lino-Silva, Leonardo Saúl ; González-Romo, Marco Aurelio ; Ramírez-Jaramillo, José Manuel ; Henson, Donald E</creatorcontrib><description>We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule. We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and leiomyosarcoma were excluded from the study. Data from the Surveillance Epidemiology and End Results program on low- and high-grade ESS for 1973 through 2003 were obtained. One uterine primary ESS had collections of clear cells (20%), while a metastatic ESS contained predominantly clear cells (90%). CD10 (88.2%) and smooth muscle actin (70.5%) were the most common positive immunohistochemical markers. The latter marker was located in the cytoplasm in 47% of the ESS and in the nucleus in 23.5%, a previously unreported feature. HMB45 was detected in 23.5% of the ESS, which contrasts with the 2% reported by other authors. The presence of clear cells and HMB45 reactivity does not justify the term perivascular epithelioid cell tumors for these neoplasms. Two of 17 patients with ESS died of metastatic disease. However, among 274 cases of ESS (all stages included) collected by the Surveillance Epidemiology and End Results Program of the National Cancer Institute during a 30-year period, the 10-year survival rate was 94%.</description><identifier>ISSN: 0002-9173</identifier><identifier>EISSN: 1943-7722</identifier><identifier>DOI: 10.1309/AJCPS88CMJRXZBWA</identifier><identifier>PMID: 24838330</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - metabolism ; Endometrial Neoplasms - metabolism ; Endometrial Neoplasms - mortality ; Endometrial Neoplasms - pathology ; Endometrium - metabolism ; Endometrium - pathology ; Female ; Humans ; Immunohistochemistry ; Melanoma-Specific Antigens - metabolism ; Middle Aged ; Sarcoma, Endometrial Stromal - metabolism ; Sarcoma, Endometrial Stromal - mortality ; Sarcoma, Endometrial Stromal - pathology ; Sarcoma, Endometrial Stromal - secondary ; Stromal Cells - metabolism ; Stromal Cells - pathology</subject><ispartof>American journal of clinical pathology, 2014-06, Vol.141 (6), p.850-855</ispartof><rights>Copyright© by the American Society for Clinical Pathology.</rights><rights>Copyright American Society for Clinical Pathology Jun 2014</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24838330$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Albores-Saavedra, Jorge</creatorcontrib><creatorcontrib>Dorantes-Heredia, Rita</creatorcontrib><creatorcontrib>Chablé-Montero, Fredy</creatorcontrib><creatorcontrib>Chanona-Vilchis, José</creatorcontrib><creatorcontrib>Pérez-Montiel, Delia</creatorcontrib><creatorcontrib>Lino-Silva, Leonardo Saúl</creatorcontrib><creatorcontrib>González-Romo, Marco Aurelio</creatorcontrib><creatorcontrib>Ramírez-Jaramillo, José Manuel</creatorcontrib><creatorcontrib>Henson, Donald E</creatorcontrib><title>Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity</title><title>American journal of clinical pathology</title><addtitle>Am J Clin Pathol</addtitle><description>We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule. We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and leiomyosarcoma were excluded from the study. Data from the Surveillance Epidemiology and End Results program on low- and high-grade ESS for 1973 through 2003 were obtained. One uterine primary ESS had collections of clear cells (20%), while a metastatic ESS contained predominantly clear cells (90%). CD10 (88.2%) and smooth muscle actin (70.5%) were the most common positive immunohistochemical markers. The latter marker was located in the cytoplasm in 47% of the ESS and in the nucleus in 23.5%, a previously unreported feature. HMB45 was detected in 23.5% of the ESS, which contrasts with the 2% reported by other authors. The presence of clear cells and HMB45 reactivity does not justify the term perivascular epithelioid cell tumors for these neoplasms. Two of 17 patients with ESS died of metastatic disease. However, among 274 cases of ESS (all stages included) collected by the Surveillance Epidemiology and End Results Program of the National Cancer Institute during a 30-year period, the 10-year survival rate was 94%.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Endometrial Neoplasms - metabolism</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrium - metabolism</subject><subject>Endometrium - pathology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Melanoma-Specific Antigens - metabolism</subject><subject>Middle Aged</subject><subject>Sarcoma, Endometrial Stromal - metabolism</subject><subject>Sarcoma, Endometrial Stromal - mortality</subject><subject>Sarcoma, Endometrial Stromal - pathology</subject><subject>Sarcoma, Endometrial Stromal - secondary</subject><subject>Stromal Cells - metabolism</subject><subject>Stromal Cells - pathology</subject><issn>0002-9173</issn><issn>1943-7722</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpd0E1Lw0AQBuBFFFurd08S8OIlOvuR7q63NlRraVH8QPESNsmGrmSTuJso_femWC-e3oF5GF4GoVMMl5iCvJos4ocnIeLV4vHtffo62UNDLBkNOSdkHw0BgIQSczpAR95_AGAigB2iAWGCCkphiFazKq-tbp1RZeBbV9ttKpf1g78OjLVdVTeuLkypg2_TrgNtm7Xyxgd1FcxXUxYFTqusNV-m3Ryjg0KVXp_scoRebmbP8Txc3t_exZNl2BAq21DmIDJWABMiUiqSSo8Jg4yzVGZpwbHAjKdZRIXudxFg4FprxbBgAmsCOR2hi9-7fbPPTvs2scZnuixVpevOJzgiY0w4Zrin5__oR925qm_XK8aYkBi26mynutTqPGmcscptkr9H0R9GWWpC</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Albores-Saavedra, Jorge</creator><creator>Dorantes-Heredia, Rita</creator><creator>Chablé-Montero, Fredy</creator><creator>Chanona-Vilchis, José</creator><creator>Pérez-Montiel, Delia</creator><creator>Lino-Silva, Leonardo Saúl</creator><creator>González-Romo, Marco Aurelio</creator><creator>Ramírez-Jaramillo, José Manuel</creator><creator>Henson, Donald E</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity</title><author>Albores-Saavedra, Jorge ; Dorantes-Heredia, Rita ; Chablé-Montero, Fredy ; Chanona-Vilchis, José ; Pérez-Montiel, Delia ; Lino-Silva, Leonardo Saúl ; González-Romo, Marco Aurelio ; Ramírez-Jaramillo, José Manuel ; Henson, Donald E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p239t-9d08c4f04885aa59ae6240c74b9cbf718147bc538e59a50107eeea418481e20d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Endometrial Neoplasms - metabolism</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrium - metabolism</topic><topic>Endometrium - pathology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Melanoma-Specific Antigens - metabolism</topic><topic>Middle Aged</topic><topic>Sarcoma, Endometrial Stromal - metabolism</topic><topic>Sarcoma, Endometrial Stromal - mortality</topic><topic>Sarcoma, Endometrial Stromal - pathology</topic><topic>Sarcoma, Endometrial Stromal - secondary</topic><topic>Stromal Cells - metabolism</topic><topic>Stromal Cells - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Albores-Saavedra, Jorge</creatorcontrib><creatorcontrib>Dorantes-Heredia, Rita</creatorcontrib><creatorcontrib>Chablé-Montero, Fredy</creatorcontrib><creatorcontrib>Chanona-Vilchis, José</creatorcontrib><creatorcontrib>Pérez-Montiel, Delia</creatorcontrib><creatorcontrib>Lino-Silva, Leonardo Saúl</creatorcontrib><creatorcontrib>González-Romo, Marco Aurelio</creatorcontrib><creatorcontrib>Ramírez-Jaramillo, José Manuel</creatorcontrib><creatorcontrib>Henson, Donald E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of clinical pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Albores-Saavedra, Jorge</au><au>Dorantes-Heredia, Rita</au><au>Chablé-Montero, Fredy</au><au>Chanona-Vilchis, José</au><au>Pérez-Montiel, Delia</au><au>Lino-Silva, Leonardo Saúl</au><au>González-Romo, Marco Aurelio</au><au>Ramírez-Jaramillo, José Manuel</au><au>Henson, Donald E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity</atitle><jtitle>American journal of clinical pathology</jtitle><addtitle>Am J Clin Pathol</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>141</volume><issue>6</issue><spage>850</spage><epage>855</epage><pages>850-855</pages><issn>0002-9173</issn><eissn>1943-7722</eissn><abstract>We describe the morphologic and immunohistochemical features of 17 endometrial stromal neoplasms, 16 sarcomas, and one stromal nodule. We reviewed 35 cases interpreted as endometrial stromal neoplasms, but 17 high-grade endometrial stromal sarcomas (ESS) and one case of mixed endometrial sarcoma and leiomyosarcoma were excluded from the study. Data from the Surveillance Epidemiology and End Results program on low- and high-grade ESS for 1973 through 2003 were obtained. One uterine primary ESS had collections of clear cells (20%), while a metastatic ESS contained predominantly clear cells (90%). CD10 (88.2%) and smooth muscle actin (70.5%) were the most common positive immunohistochemical markers. The latter marker was located in the cytoplasm in 47% of the ESS and in the nucleus in 23.5%, a previously unreported feature. HMB45 was detected in 23.5% of the ESS, which contrasts with the 2% reported by other authors. The presence of clear cells and HMB45 reactivity does not justify the term perivascular epithelioid cell tumors for these neoplasms. Two of 17 patients with ESS died of metastatic disease. However, among 274 cases of ESS (all stages included) collected by the Surveillance Epidemiology and End Results Program of the National Cancer Institute during a 30-year period, the 10-year survival rate was 94%.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>24838330</pmid><doi>10.1309/AJCPS88CMJRXZBWA</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0002-9173
ispartof American journal of clinical pathology, 2014-06, Vol.141 (6), p.850-855
issn 0002-9173
1943-7722
language eng
recordid cdi_proquest_miscellaneous_1526127141
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current)
subjects Adult
Aged
Biomarkers, Tumor - metabolism
Endometrial Neoplasms - metabolism
Endometrial Neoplasms - mortality
Endometrial Neoplasms - pathology
Endometrium - metabolism
Endometrium - pathology
Female
Humans
Immunohistochemistry
Melanoma-Specific Antigens - metabolism
Middle Aged
Sarcoma, Endometrial Stromal - metabolism
Sarcoma, Endometrial Stromal - mortality
Sarcoma, Endometrial Stromal - pathology
Sarcoma, Endometrial Stromal - secondary
Stromal Cells - metabolism
Stromal Cells - pathology
title Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A38%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Endometrial%20stromal%20sarcomas:%20immunoprofile%20with%20emphasis%20on%20HMB45%20reactivity&rft.jtitle=American%20journal%20of%20clinical%20pathology&rft.au=Albores-Saavedra,%20Jorge&rft.date=2014-06-01&rft.volume=141&rft.issue=6&rft.spage=850&rft.epage=855&rft.pages=850-855&rft.issn=0002-9173&rft.eissn=1943-7722&rft_id=info:doi/10.1309/AJCPS88CMJRXZBWA&rft_dat=%3Cproquest_pubme%3E1526127141%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1544489101&rft_id=info:pmid/24838330&rfr_iscdi=true